TITLE

Long-term β interferon in MS: safe, but what effect on disability?

PUB. DATE
August 2010
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Aug2010, Vol. 81 Issue 8, p825
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
52878974

 

Related Articles

  • Evaluating the Potential Benefit of Interferon Treatment in Multiple Sclerosis. Derfuss, Tobias; Kappos, Ludwig // JAMA: Journal of the American Medical Association;7/18/2012, Vol. 308 Issue 3, p290 

    The article offers an evaluation of interferon in treating multiple sclerosis (MS). It informs that pathological and imaging studies have shown that MS inflammation is closely associated with demyelination and with irreversible axonal and cortical damage. It mentions of a cohort study which was...

  • Beta-interferon therapy in relapsing and remitting multiple sclerosis - challenges in an emerging country. Radhakrishnan, Sureshkumar; Padmajan, Rajeswary Kalathil; Yadav, Praveen Kumar; James, Emmanuel; Anandkumar, Anandakuttan // International Journal of Nutrition, Pharmacology, Neurological D;2014 Supplement1, Vol. 4, pS34 

    Context: Multiple sclerosis (MS) is an immune-mediated demyelinating disease, with an increasing prevalence in India, as is seen in the recent studies. Beta-Interferon is the most widely used treatment option. There is a paucity of studies on beta-interferon in relapsing remitting multiple...

  • Long-term care insurance: Myths and facts. Jones, Martin V. // Inside MS;Summer94, Vol. 12 Issue 2, p19 

    Reports on the feasibility of long-term care insurance (LTCI) for people with multiple sclerosis (MS). Disability rate of people with MS; Acceptability of MS among the LTCI companies; Effectivity of LTCI in meeting long-term needs.

  • Beta-interferons in multiple sclerosis: A single center experience in India. Gupta, Salil; Varadarajulu, R.; Ganjoo, R. K. // Annals of Indian Academy of Neurology;Apr-Jun2010, Vol. 13 Issue 2, p132 

    Background: Indian-Asian multiple sclerosis behaves somewhat differently from Western disease. It is not known if the response to β-interferon is also different. Aim: To demonstrate the decrease in relapses with β-interferon in Indian patients with multiple sclerosis. Patients and Methods:...

  • Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes. Katrych, Oleksandra; Simone, Tessa M.; Azad, Shara; Mousa, Shaker A. // CNS & Neurological Disorders - Drug Targets;2009, Vol. 8 Issue 6, p512 

    Multiple sclerosis (MS) is a chronic, debilitating condition mediated by inflammation and neurodegeneration. The ultimate goal of treatment is to delay or halt the progression of irreversible disability. Disease-modifying drugs (DMDs), including beta interferon and glatiramer acetate during...

  • Intensive immunosuppression in multiple sclerosis. Zaffaroni, M.; Ghezzi, A.; Comi, G. // Neurological Sciences;May2006 Supplement 1, Vol. 27, ps13 

    Immunosuppressive drugs have been used out of label in multiple sclerosis (MS) for over 30 years and around 10% of patients are actually under immunosuppressive treatment. The rationale for immunosuppression in MS lies in the hypothesis that MS is an inflammatory immune-mediated disease that can...

  • Therapy — immunomodulation — Part I.  // Multiple Sclerosis (13524585);Sep2005 Supplement, Vol. 11, p75 

    Discusses abstracts of studies about immunomodulation and multiple sclerosis, published in the October 2005 issue of the periodical "Multiple Sclerosis". "Prevention of Chronic Black Holes With Interferon Beta-1a in Secondary Progressive MS," by A. Traboulsee and colleagues; "Design and...

  • Dünden Bugüne, Multipl Skleroz'da Hastalık Sürecini Kontrol Eden Tedaviler. ERAKSOY, Mefkûre // Archives of Neuropsychiatry / Noropsikiatri Arsivi;Dec2011 Supplement, Vol. 48, p46 

    Patients with multiple sclerosis have a lifelong disease for which no cure is currently available. Treatments for MS should demonstrate sustained efficacy to slow or stop the inflammation, demyelination or axonal damage in the central nervous system. The development of interferon beta (IFNB)...

  • Modern approaches to multiple sclerosis. Wilson, Martin // Clinical Medicine;Aug2011, Vol. 11 Issue 4, p361 

    The article discusses modern approaches to diagnosis and treatment of multiple sclerosis (MS), a common cause of neurological disability. MS has several subtypes which include relapsing-remitting MS (RRMS), progressive-relapsing MS and secondary progressive MS (SPMS). The use of magnetic...

  • Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have? Polman, Chris H.; Killestein, Joep; Schellekens, Huub // Multiple Sclerosis (13524585);Jun2006, Vol. 12 Issue 3, p245 

    The article discusses the impact of neutralizing antibodies to interferon-beta persistence after cessation of therapy. It further explains on the safeness and effectivity of interferon-beta treatment for relapsing-remitting multiple sclerosis. Long-term information on unselected patients treated...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics